Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Shares Gap Down – Time to Sell?Defense World · Oct 3, 2026
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Oct 2, 2026
Damora CEO buys 12,500 shares in open marketDefense World · Sep 29, 2026
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) CEO Jennifer Jarrett Purchases 12,500 Shares of Company StockDefense World · Sep 28, 2026
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Sep 3, 2026
Damora Therapeutics: Competition Validates The Target While Its Portfolio Creates The UpsideSeeking Alpha · Aug 12, 2026Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.41 | -$0.39 | Beat |
| May 12, 2026 | -$0.21 | -$0.62 | Miss |
| Mar 18, 2026 | -$0.14 | -$3.24 | Miss |
| Nov 6, 2025 | -$0.10 | -$2.36 | Miss |
| Aug 5, 2025 | – | -$2.60 | |
| May 8, 2025 | – | -$1.92 |